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Idiopathic pulmonary fibrosis (IPF) is a disease with a poor prognosis and very few 
available treatment options. The involvement of the purinergic receptor subtypes P2Y2 
and P2X7 in fibrotic lung disease has been demonstrated recently. In this study, we inves-
tigated the role of P2Y6 receptors in the pathogenesis of IPF in humans and in the animal 
model of bleomycin-induced lung injury. P2Y6R expression was upregulated in lung 
structural cells but not in bronchoalveolar lavage (BAL) cells derived from IPF patients as 
well as in animals following bleomycin administration. Furthermore, BAL fluid levels of the 
P2Y6R agonist uridine-5′-diphosphate were elevated in animals with bleomycin-induced 
pulmonary fibrosis. Inflammation and fibrosis following bleomycin administration were 
reduced in P2Y6R-deficient compared to wild-type animals confirming the pathophysi-
ological relevance of P2Y6R subtypes for fibrotic lung diseases. Experiments with bone 
marrow chimeras revealed the importance of P2Y6R expression on lung structural cells 
for pulmonary inflammation and fibrosis. Similar effects were obtained when animals 
were treated with the P2Y6R antagonist MRS2578. In vitro studies demonstrated that 
proliferation and secretion of the pro-inflammatory/pro-fibrotic cytokine IL-6 by lung 
fibroblasts are P2Y6R-mediated processes. In summary, our results clearly demonstrate 
the involvement of P2Y6R subtypes in the pathogenesis of pulmonary fibrosis. Thus, 
blocking pulmonary P2Y6 receptors might be a new target for the treatment of IPF.
Keywords: pulmonary fibrosis, inflammation, purinergic receptors, uridine-5′-diphosphate, animal model, 
bleomycin
inTrODUcTiOn
Idiopathic pulmonary fibrosis (IPF) is deadly lung disease, which is believed to arise from aberrant 
proliferation of fibrous tissue following tissue injury. Different cell types including inflammatory 
cells, lung fibroblasts, and abnormally activated alveolar epithelial cells have been shown to play a 
prominent role in IPF pathophysiology. Histologically characteristic changes such as myofibroblast 
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accumulation in the alveolar airspaces and excessive deposition 
of extracellular matrix components can be observed. Though 
some progress has been made, very few treatment options are 
available for IPF, at least partly due to the lack of knowledge about 
the processes regulating the progression of tissue injury to tissue 
fibrosis (1–3).
Nucleotides such as adenosine-5′-triphosphate (ATP), 
adenosine-5′-diphosphate, uridine-5′-triphosphate, or uridine-
5′-diphosphate (UDP) are released into the extracellular space 
under various conditions, including inflammation or hypoxia 
(4–7). The cellular effects of extracellular nucleotides are 
mediated via P2 purinergic receptors (P2Rs) which can be 
subdivided into G protein-coupled P2Y (P2Y1, P2Y2, P2Y4, 
P2Y6, P2Y11–P2Y14) and P2X receptors (P2X1–P2X7) which are 
ligand-gated ion channels (8). Functional P2R are expressed on 
both inflammatory and lung structural cells and P2R activation 
is associated with a broad range of cellular responses, including 
migration, cytokine secretion, release of reactive oxygen species, 
or apoptosis (5, 8, 9). The involvement of specific P2R subtypes 
in the pathophysiology of lung diseases, e.g., bronchial asthma or 
chronic obstructive pulmonary disease is well established (4, 6, 
9–11). Increased extracellular ATP levels have been measured in 
the bronchoalveolar lavage (BAL) fluid derived from IPF patients 
or animals with bleomycin-induced pulmonary fibrosis, whereas 
deficiency in distinct P2R subtypes such as P2X7R or P2Y2R was 
associated with reduced inflammation and fibrosis following 
bleomycin administration (12–14). Nevertheless, as the expres-
sion of purinergic receptors is widespread, the involvement of 
more than one P2R subtype is likely.
In contrast to other P2R subtypes, the P2Y6 receptor is 
preferentially activated by UDP and not by ATP (9, 15, 16). 
P2Y6 receptors have been linked with the pathophysiology of 
inflammatory bowel disease, vascular inflammation, and cardiac 
fibrosis (17–19). Previously, we were able to demonstrate that 
P2Y6 receptors contribute to acute and chronic allergic airway 
inflammation (9). However, the role of this receptor subtype in 
the context of fibrotic lung disease has not been investigated in 
detail yet.
MaTerials anD MeThODs
Patient Materials
Bronchoalveolar lavage fluids were collected from patients 
undergoing bronchoscopy during the diagnostic workup of IPF 
or from healthy volunteers. In addition, surgical lung biopsies 
derived from IPF patients or tumor free margins of lung cancer 
resections as control were used. IPF was diagnosed according to 
published criteria (20). The study was approved by the local ethics 
committee (ethics committee at the University Medical Center 
Freiburg).
animals
P2Y6R-deficient and wild-type (WT) animals (both on 
C57BL/6 background) were bred at the University Freiburg. All 
experiments were approved by the local animal ethics committee 
(Regierungspräsidium Freiburg).
generation of chimeric animals with 
P2Y6r Deficiency on hematopoietic or 
structural cells
Wild-type or P2Y6R-deficient mice were given 5 × 106 bone mar-
row cells derived from WT or P2Y6R-deficient animals intrave-
nously after irradiation with 900 cGy (2× 450 cGy). The following 
donor/recipient pairs were combined: WT BM → WT, P2Y6R−/− 
BM → WT, WT BM → P2Y6R−/− and P2Y6R−/− BM → P2Y6R−/−.
Bleomycin Model of Pulmonary Fibrosis
Male C57BL/6 or P2Y6R-deficient animals (6–8  weeks old) 
were anesthetized via intraperitoneal injection with ketamine/
xylazine (2/0.1  mg) and received an intratracheal (i.t.) injec-
tion of bleomycin (80  µl; 0.5  mg/ml). In some experiments, 
animals were treated intratracheally with the P2Y6R antagonist 
MRS2578 or vehicle in either a prophylactic (d0, d5, d10 after 
bleomycin application) or therapeutic protocol (from day 14 
after bleomycin application, for three times a week). Animals 
were killed at different time points via intraperitoneal (i.p.) 
injection of pentobarbital as indicated. BAL was performed 
with 3× 1 ml of Ca2+- and Mg2+-free PBS supplemented with 
0.1  mM sodium EDTA, followed by lung resection and stor-
age in OCT freezing medium. BAL cells were counted using 
a hemocytometer, and differential cell counts were done by 
fluorescence-activated cell sorter (FACS) analysis, as described 
previously (21). Briefly BAL cells were stained for 30 min with 
anti-Ly6 B FITC (Serotec, Düsseldorf, Germany), anti-F4/80 Pe 
(eBioscience, San Diego, CA, USA), anti-CD3 and anti-CD19 
cy-chrome (eBioscience, San Diego, CA, USA), and anti-CD45 
APC (ImmunoTools, Friesoythe, Germany) in PBS containing 
0.5% BSA followed by FACS analysis. Frozen lung sections 
were stained with hematoxylin/eosin for histological analysis. 
Lung slides were also stained with picrosirius red for collagen 
quantification. Therefore, frozen lung sections were incubated 
in picrosirius red solution for 1  h. After washing with water, 
tissue sections were stained with hematoxylin for 5–10 s. Slides 
were washed with running tap water and dehydrated in 70%, 
90%, and absolute ethanol, followed by xylene. Entellan (Merck) 
was used to mount the coverslip. Images were obtained using 
Axio Lab.A1 microscope (Zeiss) with 200× magnification and 
AxioCam ICc1 (Zeiss). Collagen quantification was made with 
ImageJ software (21).
Mediator Measurements in BalF
Uridine-5′-diphosphate concentrations in BALF were measured 
by HPLC as previously described (22). BALF collagen content 
was measured by Sircol assay (Biocolor, Carrickfergus, UK). The 
concentration of cytokines in the BAL fluid was determined by 
ELISA (R&D Systems, Minneapolis, MN, USA).
Pcr
Total RNA from human or murine lung tissue was isolated 
using RNeasy mini-kits (Qiagen, Hilden, Germany) according 
to the manufacturer’s recommendations followed by reverse 
transcription using Stratascript reverse transcriptase (Stratagene, 
La Jolla, CA, USA) and random primers (Invitrogen, Karlsruhe, 
FigUre 1 | P2Y6R expression in idiopathic pulmonary fibrosis (IPF).  
(a) Immunohistochemical stainings for P2Y6R expression were performed 
with lung tissue derived from IPF patients (n = 5) or controls (tumor-free 
margins from lung cancer resections; n = 5). (B) Bronchoalveolar lavage cells 
derived from IPF patients (n = 5) and healthy volunteers (n = 5) were stained 
for P2Y6R expression.
FigUre 2 | P2Y6R expression in bleomycin-induced pulmonary fibrosis. 
Male C57Bl/6 mice received an i.t. injection of BLM or vehicle on day 0. 
Animals were killed at the indicated time points and P2Y6R expression in 
lung tissue was analyzed by quantitative RT-PCR (n = 3–4 per group) 
(*p < 0.05).
FigUre 3 | Elevated extracellular uridine-5′-diphosphate (UDP) levels in 
bleomycin-induced pulmonary fibrosis. Male C57Bl/6 mice received an i.t. 
injection of BLM or vehicle on day 0. Animals were killed at the indicated time 
points, and UDP levels were measured in the bronchoalveolar lavage fluid 
(n = 4–6 per group) (**p < 0.01; ***p < 0.001).
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Germany). Quantitative PCR was performed with Taqman 
Universal PCR Mastermix (Applied Biosystems, Foster City, CA, 
USA) and pre-formulated primers and probe mixes (Assay on 
Demand; Applied Biosystems). PCR was performed on a thermal 
cycler (iCycler; Bio-Rad, Hercules, CA, USA). PCR amplification 
of the housekeeping gene encoding glyceraldehyde 3-phosphate 
dehydrogenase was performed during each run for each sample 
to allow normalization between samples.
isolation of Primary Murine  
lung Fibroblasts
Lungs of P2Y6R-deficient or WT animals were excised and cut 
in small pieces, followed by digestion with collagenase. Single 
cell suspensions were obtained by passing through a cell strainer. 
Cells were plated on six-well plates in cell culture medium at 
37°C, 5% CO2 in a humidified atmosphere. Medium was changed 
every 2 or 3 days. Cells were trypsinized after 14 days and used for 
experiments. Purity of isolated cells was assessed by microscopy 
(typical morphology of fibroblasts) (23).
isolation of Primary human  
lung Fibroblasts
Primary lung Fibroblasts were isolated as described previously 
(23). Briefly, histologically normal lung tissue was obtained from 
resected lung specimens from subjects with central lung cancers 
or from patients with benign tumors. Lung tissue was sliced and 
washed. The washed slices were placed into six-well plates con-
taining Quantum (PAA, Pasching, Austria) and 1% penicillin/
streptomycin solution. The slices were maintained in the medium 
at 37°C in a 5% CO2 incubator for 2–3 weeks. The cells that grew 
from these tissue slices were serially passaged several times to 
yield pure populations of lung FBRs. The fibroblast cell lines were 
assessed by cell morphology, immunostaining for vimentin, and 
FACS analysis.
Proliferation of lung Fibroblasts
Fibroblasts (2 × 105 cells/well) were seeded into cell culture plates 
and stimulated with UDP or vehicle (sterile phosphate-buffered 
saline). Higher concentrations of FCS were used as a positive 
control. After 48 h, cells were trypsinized and counted. Results 
are shown as proliferation index, calculated as the number of 
cells stimulated with UDP divided by the number of vehicle-
treated cells.
Measurement of s6 Phosphorylation
Fibroblasts were stimulated with the indicated nucleotides or 
vehicle. Cells were lysed with RIPA buffer at different time points. 
FigUre 4 | P2Y6R in bleomycin-induced pulmonary fibrosis. P2Y6R-deficient or wild-type (WT) mice received an i.t. injection of BLM or vehicle on day 0 and were 
killed 7, 14, or 21 days later. Total and differential cell counts of the BALF were performed (a). BALF cytokines were measured by ELISA (B). Collagen contents of 
the BALF were quantified by Sircol assay [(c), left panel] or on histological lung slides [(c), right panel]. Representative histological staining of lung slides  
(D). n = 4–14 per group. *p < 0.05 BLM-treated P2Y6R-deficient compared to BLM-treated WT animals at the same time point.
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Cell lysates were analyzed by immunoblot using antibodies for 
phospho-S6 (Cell Signaling Technology, USA) and Actin (Sigma, 
Steinheim, Germany).
statistical analysis
If not stated otherwise, groups were compared using one-way 
ANOVA, followed by Bonferroni comparison test (GraphPad 
FigUre 5 | Involvement of P2Y6R subtypes on inflammatory and lung 
structural cells in bleomycin-induced pulmonary fibrosis. The indicated 
chimeric animals were generated. Mice received an intratracheal application 
of BLM on day 0. Bronchoalveolar lavage total and differential cell counts 
were performed, (a) and cytokine concentrations were measured by ELISA 
(B) at day 14. n = 5–8 per group. *p < 0.05 compared to WT BM → WT or 
to P2Y6R−/− BM → WT.
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Prism Software, San Diego, CA, USA). A p-value <0.05 was 
considered as significant.
resUlTs
Previous studies have demonstrated that P2Y6R expression on 
epithelial cells is upregulated following inflammatory stimuli (9). 
Therefore, histological lung slides and BAL cells were stained for 
P2Y6R expression. As shown in Figure 1, P2Y6R expression was 
upregulated on lung structural cells in the alveolar space derived 
from IPF patients whereas no changes were seen on BAL cells 
(Figure 1; Figure S1 in Supplementary Material).
To confirm the pathophysiological relevance of our find-
ings in  vivo, we switched to the established mouse model of 
bleomycin-induced pulmonary fibrosis. As a first approach, 
P2Y6R expression in whole lung tissue was analyzed at different 
time points after intratracheal injection of bleomycin or vehicle. 
Thereby, we observed an upregulation of P2Y6R expression with 
a maximum at day 14 after bleomycin exposure with a decline at 
later time points (Figure 2).
Adenosine-5′-triphosphate is abundantly released into the 
extracellular space under different conditions (4–6, 12, 14). By 
contrast, much less is known about the potent P2Y6R agonist 
UDP. The concentration of UDP was significantly increased in the 
BAL fluid after bleomycin exposure with a maximal concentra-
tion at day 7 and a decline at later time points (Figure 3).
To address whether targeting P2Y6 receptors might be an 
approach for the treatment of fibrotic lung disease P2Y6R-deficient 
or WT animals received an intratracheal injection of bleomycin 
or vehicle at day 0. The degree of inflammation and fibrosis was 
determined at different time points (7, 14, and 21  days after 
bleomycin administration). As shown in Figure  4, there was a 
reduction in pulmonary inflammation at all mentioned time 
points demonstrated by a reduced number of inflammatory cells 
in the BAL fluid (Figure 4A) paralleled by a decreased concentra-
tion of the pro-inflammatory cytokines IL-6 and keratinocyte-
derived chemokine (Figure  4B). In addition, fibrotic tissue 
remodeling after bleomycin administration was also reduced in 
P2Y6R-deficient demonstrated by reduced collagen content of 
the BAL fluid and on histological lung slides (Figures  4C,D). 
Furthermore, BAL fluid levels of the pro-fibrotic cytokine TGF-β 
was significantly lower in P2Y6R-deficient animals (Figure  4B 
right panel).
Next, we sought to determine the relative involvement of P2Y6 
receptors on hematopoietic and lung structural cells. Therefore, 
the following bone marrow chimeric mice were generated and 
exposed to bleomycin: WT BM →  WT, P2Y6R−/− BM →  WT, 
WT BM → P2Y6R−/−, and P2Y6R−/− BM → P2Y6R−/−. As shown 
in Figure  5, the loss of P2Y6R expression on lung structural 
(WT BM → P2Y6R−/− and P2Y6R−/− BM → P2Y6R−/−) but not on 
hematopoietic cells (P2Y6R−/− BM → WT) was associated with 
a significant decrease in bleomycin-induced lung inflammation.
We next questioned whether treatment with a specific P2Y6R 
antagonist would have similar effects as P2Y6R deficiency. 
Therefore, animals were treated with the P2Y6R antagonist 
MRS2578 according to two different protocols: in the prophy-
lactic protocol animals received an intratracheal bleomycin 
injection on day 0 and were treated with MRS2578 or vehicle after 
5 h, 5 days, and 10 days. As shown in Figure 6, treatment with 
MRS2578 decreased pulmonary inflammation at day 7 and day 
14 after bleomycin administration demonstrated by a reduced 
number of inflammatory cells (Figure 6A) and reduced levels of 
pro-inflammatory mediators in the BAL fluid (Figure 6B), and on 
histological lung slides (Figure 6C). To address fibrotic changes 
during the late phase after bleomycin administration, another 
protocol (therapeutic protocol) was used in which treatment 
with MRS2578 or vehicle was started at day 14 for three times 
a week. Likewise, inflammation (Figures  6D,E,G) and fibrosis 
(Figure 6F) were decreased in MRS2578-treated animals on day 
21 and day 30 after bleomycin exposure.
In pursuit of the mechanisms involved in P2Y6R-induced 
progression of pulmonary inflammation and fibrosis, in  vitro 
experiments with human and murine cells were performed. To 
check the involvement of P26R subtypes in regulating the prolif-
eration rate of lung fibroblasts, primary murine lung fibroblasts 
were treated with UDP or vehicle as a negative control and cell 
proliferation was assessed after 48  h. Thereby, UDP increased 
fibroblast proliferation (Figure  7A, left panel), an effect which 
could not be observed with cells derived from P2Y6R-deficient 
animals. Similar results were obtained with primary human 
lung fibroblasts (Figure  7A, right panel). Next, we questioned 
whether P26R signaling is also involved in IL-6 production by 
lung fibroblasts, a cytokine involved both in acute inflammation 
and tissue remodeling (24). UDP dose dependently increased 
IL-6 production by murine (Figure 7B, left panel) and human 
(Figure 6B, right panel) fibroblasts via activation of P2Y6R sub-
types (Figure 7B, middle). Activation of the S6–mTOR pathway 
in fibroblasts plays an important role in the pathogenesis of lung 
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FigUre 6 | Blocking P2Y6R subtypes decreases bleomycin-induced pulmonary fibrosis. Male C57Bl/6 mice received an i.t. application of BLM on day 0 and were 
treated with the P2Y6R antagonist MRS2578 or vehicle according to the prophylactic (a–c) or therapeutic (D–g) protocol. Total and differential cell counts of the 
BALF were performed (a,D). BALF cytokines were measured by ELISA (B,e). Collagen contents of the BALF were quantified by Sircol assay [(F), left panel] or on 
histological lung slides [(F), right panel]. Representative histological staining of lung slides (c,g). *p < 0.05 compared to BLM/vehicle-treated animals at the same 
time point.
fibrosis (25). Therefore, we next determined the effect of UDP on 
Akt and S6 phosphorylation showing that stimulation with UDP 
resulted in a transient activation of pS6 (Figure 7C).
DiscUssiOn
Signaling via purinergic receptors has been demonstrated to be 
crucial for the pathophysiology of various lung disorders includ-
ing pulmonary fibrosis (8, 14). As we were previously able to show 
that the activation of P2Y6 receptors is associated with inflam-
mation and tissue remodeling in an animal model of allergic 
lung inflammation, we were interested whether this purinergic 
receptor subtype is also involved in the pathogenesis of fibrotic 
lung diseases (9).
We observed an upregulation of pulmonary P2Y6R 
expression in animals with bleomycin-induced lung fibrosis. 
Immunohistochemical staining of human lung tissue samples 
showed an upregulation of P2Y6R expression on lung structural 
cells in patients suffering from IPF though samples from only few 
patients were available which has to be considered as a limitation 
of our study. Nevertheless, these results are in line with previous 
studies showing increased P2Y6R expression on resident cells 
under inflammatory conditions (9, 17, 26). Interestingly, as ble-
omycin-induced pulmonary fibrosis is known to be self-limiting 
there was a decline in P2Y6R expression at later time points (27). 
In addition to P2Y6R expression, the concentration of UDP which 
is the strongest naturally occurring agonist at P2Y6 receptors was 
also elevated following bleomycin administration. While numer-
ous studies demonstrated increased extracellular ATP levels in 
inflamed tissues, much less is known about the release of UPD 
into the extracellular space in the context of inflammation or 
tissue remodeling (4, 5, 12, 28).
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FigUre 7 | P2Y6Rs induce proliferation and cytokine secretion of lung fibroblasts. Primary murine lung fibroblasts were generated from wild-type or P2Y6R-deficient 
animals. The proliferation rate after stimulation with uridine-5′-diphosphate (UDP) was determined [(a), left panel]. Proliferation rate of human primary lung fibroblasts 
after pre-incubation with the P2Y6R antagonists MRS2578 and stimulation with UDP [(a), right panel]. IL-6 release of primary murine [(B), left panel and middle] and 
human [(B), right panel] lung fibroblasts stimulated with UDP was measured by ELISA. S6 phosphorylation after stimulation with UDP was measured by Western 
Blot at the indicated time points. One representative experiment out of three is shown (c). n = 3–5 per group (*p < 0.05).
The degree of inflammation and fibrosis following bleomycin 
administration was attenuated in P2Y6R-deficient animals com-
pared to WT animals. Similar results were obtained when WT 
animals were treated with the P2Y6R antagonist MRS2578. While 
the role of P2Y6 receptors in the context of acute inflammation, 
e.g., acute allergic airway, intestinal or vascular inflammation, has 
been studied extensively much less is known about the role of 
this receptor subtype in tissue remodeling and fibrosis, though 
in an animal model of chronic allergic airway inflammation, 
P2Y6R activation was also associated with airway remodeling 
(9, 17, 26). In accordance, another study demonstrated UDP and 
ATP release by cardiomyocytes triggered by mechanical stretch 
leading to P2Y6R-dependent cardiac fibrosis (19).
An upregulation of P2Y6R expression in lung structural derived 
from IPF patients and animals after bleomycin administration 
was observed. In addition, experiments with chimeric animals 
revealed that P2Y6R expression on lung structural rather than on 
immune cells was responsible for P2Y6R-induced inflammation 
and fibrosis in accordance with previous studies (9, 17). Hence, 
in vitro experiments with lung fibroblasts were performed in pur-
suit of the involved mechanisms. Thereby, we were able to show 
that UDP increased the proliferation rate of human and murine 
lung fibroblasts via activation of P2Y6 receptors. Similar results 
have been made previously with different cell types though the 
effect of P2Y6R activation on the proliferation rate of fibroblasts 
has not been studied in detail, yet (29, 30).
Apart from the synthesis and the release of extracellular 
matrix components, lung fibroblasts have also been demon-
strated to exert immune-regulatory properties. Stimulation of 
primary lung fibroblasts resulted in increased production of 
the pro-inflammatory cytokine IL-6 which is associated with 
tissue remodeling (24, 31–33). This is in a line with previous 
work which demonstrated the importance of P2Y6-triggered 
release of pro-inflammatory cytokines by epithelial cells for 
the pathogenesis of bronchial asthma or inflammatory bowel 
disease (9, 17).
8Müller et al. P2Y6 Receptors and Pulmonary Fibrosis
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 1028
reFerences
1. King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet (2011) 
378:1949–61. doi:10.1016/S0140-6736(11)60052-4 
2. King  TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, 
Glassberg MK, et  al. A phase 3 trial of pirfenidone in patients with idio-
pathic pulmonary fibrosis. N Engl J Med (2014) 370:2083–92. doi:10.1056/
NEJMoa1402582 
3. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. 
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl 
J Med (2014) 370:2071–82. doi:10.1056/NEJMoa1402584 
4. Idzko M, Hammad H, van Nimwegen M, Kool M, Willart MA, Muskens F, 
et al. Extracellular ATP triggers and maintains asthmatic airway inflammation 
by activating dendritic cells. Nat Med (2007) 13:913–9. doi:10.1038/nm1617 
5. Lommatzsch M, Cicko S, Müller T, Lucattelli M, Bratke K, Stoll P, et  al. 
Extracellular adenosine triphosphate and chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med (2010) 181:928–34. doi:10.1164/
rccm.200910-1506OC 
6. Cicko S, Lucattelli M, Müller T, Lommatzsch M, De Cunto G, Cardini S, et al. 
Purinergic receptor inhibition prevents the development of smoke-induced 
lung injury and emphysema. J Immunol (2010) 185:688–97. doi:10.4049/
jimmunol.0904042 
7. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, et al. 
Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling 
in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B 
receptors. J Exp Med (2003) 198:783–96. doi:10.1084/jem.20030891 
8. Idzko M, Ferrari D, Eltzschig HK. Nucleotide signalling during inflammation. 
Nature (2014) 509:310–7. doi:10.1038/nature13085 
9. Vieira RP, Müller T, Grimm M, von Gernler V, Vetter B, Dürk T, et  al. 
Purinergic receptor type 6 contributes to airway inflammation and remodel-
ing in experimental allergic airway inflammation. Am J Respir Crit Care Med 
(2011) 184:215–23. doi:10.1164/rccm.201011-1762OC 
10. Müller T, Vieira RP, Grimm M, Dürk T, Cicko S, Zeiser R, et al. A potential role 
for P2X7R in allergic airway inflammation in mice and humans. Am J Respir 
Cell Mol Biol (2011) 44:456–64. doi:10.1165/rcmb.2010-0129OC 
11. Lucattelli M, Cicko S, Müller T, Lommatzsch M, De Cunto G, Cardini S, 
et  al. P2X7 receptor signaling in the pathogenesis of smoke-induced lung 
inflammation and emphysema. Am J Respir Cell Mol Biol (2011) 44:423–9. 
doi:10.1165/rcmb.2010-0038OC 
12. Riteau N, Gasse P, Fauconnier L, Gombault A, Couegnat M, Fick L, et  al. 
Extracellular ATP is a danger signal activating P2X7 receptor in lung 
inflammation and fibrosis. Am J Respir Crit Care Med (2010) 182:774–83. 
doi:10.1164/rccm.201003-0359OC 
13. Monção-Ribeiro LC, Faffe DS, Santana PT, Vieira FS, da Graça CL, Marques-
da-Silva C, et al. P2X7 receptor modulates inflammatory and functional pul-
monary changes induced by silica. PLoS One (2014) 9:e110185. doi:10.1371/
journal.pone.0110185 
14. Müller T, Fay S, Vieira RP, Karmouty-Quintana H, Cicko S, Ayata K, et al. 
The purinergic receptor subtype P2Y2 mediates chemotaxis of neutrophils 
and fibroblasts in fibrotic lung disease. Oncotarget (2017) 8(22):35962–72. 
doi:10.18632/oncotarget.16414 
15. Kukulski F, Ben Yebdri F, Lecka J, Kauffenstein G, Lévesque SA, Martín-
Satué M, et al. Extracellular ATP and P2 receptors are required for IL-8 to 
induce neutrophil migration. Cytokine (2009) 46:166–70. doi:10.1016/j.
cyto.2009.02.011 
16. Kukulski F, Ben Yebdri F, Lefebvre J, Warny M, Tessier PA, Sévigny J. 
Extracellular nucleotides mediate LPS-induced neutrophil migration in vitro 
and in vivo. J Leukoc Biol (2007) 81:1269–75. doi:10.1189/jlb.1206758 
17. Grbic DM, Degagné E, Langlois C, Dupuis A-A, Gendron F-P. Intestinal 
inflammation increases the expression of the P2Y6 receptor on epithelial 
cells and the release of CXC chemokine ligand 8 by UDP. J Immunol (2008) 
180:2659–68. doi:10.4049/jimmunol.180.4.2659 
18. Stachon P, Peikert A, Michel NA, Hergeth S, Marchini T, Wolf D, et al. P2Y6 defi-
ciency limits vascular inflammation and atherosclerosis in mice. Arterioscler 
Thromb Vasc Biol (2014) 34:2237–45. doi:10.1161/ATVBAHA.114.303585 
19. Nishida M, Sato Y, Uemura A, Narita Y, Tozaki-Saitoh H, Nakaya M, et al. 
P2Y6 receptor-Galpha12/13 signalling in cardiomyocytes triggers pressure 
overload-induced cardiac fibrosis. EMBO J (2008) 27:3104–15. doi:10.1038/
emboj.2008.237 
20. Travis WD, Costabel U, Hansell DM, King  TE Jr, Lynch DA, Nicholson AG, 
et  al. An official American Thoracic Society/European Respiratory Society 
statement: update of the international multidisciplinary classification of 
the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 
188:733–48. doi:10.1164/rccm.201308-1483ST 
21. Cicko S, Grimm M, Ayata K, Beckert J, Meyer A, Hossfeld M, et al. Uridine 
supplementation exerts anti-inflammatory and anti-fibrotic effects in an 
animal model of pulmonary fibrosis. Respir Res (2015) 16:105. doi:10.1186/
s12931-015-0264-9 
22. Lazarowski ER. Quantification of extracellular UDP-galactose. Anal Biochem 
(2010) 396:23–9. doi:10.1016/j.ab.2009.08.022 
23. Prasse A, Pechkovsky DV, Toews GB, Jungraithmayr W, Kollert F, Goldmann T, 
et  al. A vicious circle of alveolar macrophages and fibroblasts perpetuates 
Stimulation with UDP increased S6 phosphorylation in lung 
fibroblasts indicating the activation of the S6–mTOR pathway 
which has been shown to contribute to the pathogenesis of pul-
monary fibrosis (25, 34, 35). Apart from this, mTOR activation 
has also been observed after stimulation with ATP suggesting the 
importance of different purinergic receptor subtypes (36).
In summary, we could show the involvement of the puriner-
gic receptor subtype P2Y6 into the pathogenesis of pulmonary 
fibrosis in human and mice via several mechanisms. However, 
further studies are needed to investigate if targeting P2Y6 recep-
tors might be a new approach for the treatment of pulmonary 
fibrosis in humans.
eThics sTaTeMenT
Animal experiments were carried out in accordance with national 
regulations. All experiments were approved by the local animal 
ethics committee (Regierungspräsidium Freiburg). The use of 
Patient materials was approved by the ethics committee at the 
University Medical Center Freiburg. All subjects gave written 
informed consent in accordance with the Declaration of Helsinki.
aUThOr cOnTriBUTiOns
Experiments were planned, performed, and analyzed by TM, SF, 
RV, SC, TG, CKA, and ERL. HK-Q, GZ, and MI helped with the 
analysis of the experiments. The manuscript was written by TM, 
HK-Q, GL, DF, FV, BR, J-MB, MB, and MI. The manuscript was 
read and approved by all the authors.
FUnDing
This work was supported by a grant from the German Research 
Foundation (DFG) to TM (grant ID MU 3194/2-1), a DFG grant 
to MI (grant ID ID 7/4-1), and a grant from the NIH (National 
Heart, Lung, and Blood Institute P01-HL110873) to ERL.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found 
online at http://journal.frontiersin.org/article/10.3389/fimmu. 
2017.01028/full#supplementary-material.
9Müller et al. P2Y6 Receptors and Pulmonary Fibrosis
Frontiers in Immunology | www.frontiersin.org August 2017 | Volume 8 | Article 1028
pulmonary fibrosis via CCL18. Am J Respir Crit Care Med (2006) 173:781–92. 
doi:10.1164/rccm.200509-1518OC 
24. Saito F, Tasaka S, Inoue K, Miyamoto K, Nakano Y, Ogawa Y, et al. Role of 
interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am 
J Respir Cell Mol Biol (2008) 38:566–71. doi:10.1165/rcmb.2007-0299OC 
25. Korfhagen TR, Le Cras TD, Davidson CR, Schmidt SM, Ikegami M, Whitsett JA, 
et  al. Rapamycin prevents transforming growth factor-alpha-induced pul-
monary fibrosis. Am J Respir Cell Mol Biol (2009) 41:562–72. doi:10.1165/
rcmb.2008-0377OC 
26. Riegel AK, Faigle M, Zug S, Rosenberger P, Robaye B, Boeynaems JM, et al. 
Selective induction of endothelial P2Y6 nucleotide receptor promotes vas-
cular inflammation. Blood (2011) 117:2548–55. doi:10.1182/blood-2010-10- 
313957 
27. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol 
Lung Cell Mol Physiol (2008) 294:L152–60. doi:10.1152/ajplung.00313.2007 
28. Shi JP, Wang SY, Chen LL, Zhang XY, Zhao YH, Du B, et al. P2Y6 contributes 
to ovalbumin-induced allergic asthma by enhancing mast cell function in 
mice. Oncotarget (2016) 7:60906–18. doi:10.18632/oncotarget.11758 
29. Braganhol E, Kukulski F, Lévesque SA, Fausther M, Lavoie EG, Zanotto-
Filho A, et al. Nucleotide receptors control IL-8/ CXCL8 and MCP-1/ CCL2 
secretions as well as proliferation in human glioma cells. Biochim Biophys Acta 
(2015) 1852:120–30. doi:10.1016/j.bbadis.2014.10.014 
30. Ko T, An HJ, Ji YG, Kim OJ, Lee DH. P2Y receptors regulate proliferation 
of human pancreatic duct epithelial cells. Pancreas (2012) 41:1. doi:10.1097/
MPA.0b013e31823ba3b3 
31. Keane MP, Arenberg DA, Lynch  JP III, Whyte RI, Iannettoni MD, Burdick MD, 
et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in 
idiopathic pulmonary fibrosis. J Immunol (1997) 159:1437–43. 
32. Russo RC, Guabiraba R, Garcia CC, Barcelos LS, Roffê E, Souza AL, et  al. 
Role of the chemokine receptor CXCR2 in bleomycin-induced pulmonary 
inflammation and fibrosis. Am J Respir Cell Mol Biol (2009) 40:410–21. 
doi:10.1165/rcmb.2007-0364OC 
33. Pedroza M, Schneider DJ, Karmouty-Quintana H, Coote J, Shaw S, Corrigan 
R, et al. Interleukin-6 contributes to inflammation and remodeling in a model 
of adenosine mediated lung injury. PLoS One (2011) 6:e22667. doi:10.1371/
journal.pone.0022667 
34. Gui YS, Wang L, Tian X, Li X, Ma A, Zhou W, et al. mTOR overactivation and 
compromised autophagy in the pathogenesis of pulmonary fibrosis. PLoS One 
(2015) 10(9):e0138625. doi:10.1371/journal.pone.0138625 
35. Park JS, Park HJ, Park YS, Lee SM, Yim JJ, Yoo CG, et  al. Clinical signifi-
cance of mTOR, ZEB1, ROCK1 expression in lung tissues of pulmonary 
fibrosis patients. BMC Pulm Med (2014) 14:168. doi:10.1186/1471-2466- 
14-168 
36. Chi Y, Gao K, Li K, Nakajima S, Kira S, Takeda M, et al. Purinergic control of 
AMPK activation by ATP released through connexin 43 hemichannels – piv-
otal roles in hemichannel-mediated cell injury. J Cell Sci (2014) 127:1487–99. 
doi:10.1242/jcs.139089 
Conflict of Interest Statement: The authors declare that the research was 
conducted in the absence of any commercial or financial relationships that could 
be construed as a potential conflict of interest.
Copyright © 2017 Müller, Fay, Vieira, Karmouty-Quintana, Cicko, Ayata, Zissel, 
Goldmann, Lungarella, Ferrari, Di Virgilio, Robaye, Boeynaems, Lazarowski, 
Blackburn and Idzko. This is an open-access article distributed under the terms of 
the Creative Commons Attribution License (CC BY). The use, distribution or repro-
duction in other forums is permitted, provided the original author(s) or licensor are 
credited and that the original publication in this journal is cited, in accordance with 
accepted academic practice. No use, distribution or reproduction is permitted which 
does not comply with these terms.
